GlassScriptPhysician profile
Babar Hassan
NPI 1881680841
$1,342.51
in general payments reported to CMS, 2019-2025
14 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.53 · 2021: $353 · 2022: $170 · 2023: $232 · 2024: $357 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $582.93 | 2020-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.61 | 2020-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $91.08 | 2022-2024 | Airsupra, Breztri |
| Philips North America LLC | $89.73 | 2024 | (Ak6) Vest Therapy |
| Olympus America INC. | $64.83 | 2023 | Spiration Valve System |
| Regeneron Healthcare Solutions, INC. | $49.27 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $40.52 | 2021 | |
| Zoll Respicardia, INC. | $34.46 | 2024 | Remede System |
| Takeda Pharmaceuticals U.S.A., INC. | $22.51 | 2025 | Glassia |
| Viatris Specialty LLC | $20.35 | 2025 | Yupelri |
| Harmony Biosciences LLC | $15.97 | 2021 | |
| Genzyme Corporation | $15.30 | 2021 | |
| 3b Medical, INC. | $15.01 | 2025 | Luna |
| Teva Pharmaceuticals USA, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babar Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.